Oramed Pharmaceuticals Inc ORMP Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$3.86 down $0.03, 0.77% at close Nov 6
Last close · Previous close $3.89
- Market cap
- $157.97MAt the Nov 6 close
- P/E ratio
- 0.94On last 12 months’ EPS
- Diluted EPS
- $4.12Last 12 months
- Dividend yield
- 6.48%Last 12 months
Price chart
$3.86down $0.03, 0.77%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$3.89Nov 5
- Volume112.54KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume124.55KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.19 to $5.47; now $3.86
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ORMP beat the S&P 500 in 3 of 7 periods.
| Period | ORMP and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ORMP: down 11.9% S&P 500: down 5.6% | ORMP trailed the S&P 500 by 6.3 percentage points Trailed |
| 3M | ORMP: down 10.2% S&P 500: down 4.1% | ORMP trailed the S&P 500 by 6.1 percentage points Trailed |
| YTD | ORMP: up 44.6% S&P 500: up 8.7% | ORMP beat the S&P 500 by 35.9 percentage points Beat |
| 1Y | ORMP: up 87.4% S&P 500: up 10.9% | ORMP beat the S&P 500 by 76.5 percentage points Beat |
| Long term | ||
| 3Y | ORMP: up 111.4% S&P 500: up 75.0% +28.3% vs +20.5% a year | ORMP beat the S&P 500 by 36.4 percentage points Beat |
| 5Y | ORMP: down 84.6% S&P 500: up 67.8% −31.2% vs +10.9% a year | ORMP trailed the S&P 500 by 152.4 percentage points Trailed |
| 10Y | ORMP: down 31.3% S&P 500: up 313.1% −3.7% vs +15.2% a year | ORMP trailed the S&P 500 by 344.4 percentage points Trailed |
$10,000 invested in ORMP 10 years ago (Nov 4, 2016) would be worth about $6,870 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
ORMP beat the S&P 500 in 3 of 7 periods.
| Period | ORMP and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ORMP: down 11.9% S&P 500: down 5.6% | ORMP trailed the S&P 500 by 6.3 percentage points Trailed |
| 3M | ORMP: down 10.2% S&P 500: down 4.3% | ORMP trailed the S&P 500 by 5.9 percentage points Trailed |
| YTD | ORMP: up 35.4% S&P 500: up 7.8% | ORMP beat the S&P 500 by 27.6 percentage points Beat |
| 1Y | ORMP: up 75.5% S&P 500: up 9.7% | ORMP beat the S&P 500 by 65.8 percentage points Beat |
| Long term | ||
| 3Y | ORMP: up 97.9% S&P 500: up 68.8% +25.6% vs +19.1% a year | ORMP beat the S&P 500 by 29.1 percentage points Beat |
| 5Y | ORMP: down 85.6% S&P 500: up 56.9% −32.1% vs +9.4% a year | ORMP trailed the S&P 500 by 142.5 percentage points Trailed |
| 10Y | ORMP: down 35.7% S&P 500: up 252.6% −4.3% vs +13.4% a year | ORMP trailed the S&P 500 by 288.3 percentage points Trailed |
$10,000 invested in ORMP 10 years ago (Nov 4, 2016) would be worth about $6,433 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$29.75
Closing high on . Now 87.0% below that record.
Split-adjusted daily closes since Apr 21, 2006.
Stock splits
1
1-for-12 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
0.9×The Nov 6 close ÷ diluted EPS over the last 12 months ($4.12)
The range covers daily P/E ratios from Oct 28, 2021 to Nov 6, 2026, each based on the previous 12 months of earnings.
ORMP trades at 0.9× its earnings over the last 12 months, below its 5-year median of 2.7×. In plain terms, buyers are paying about $1 for each $1 of profit from the past year. How to read P/E
Other valuation measures
- 0.5×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - 0.9×Last 12 months’ EBITDA
Enterprise value divided by EBITDA over the last 12 months. It compares companies with different amounts of debt.
EV/EBITDA = Enterprise value ÷ EBITDA (last 12 months)EV/EBITDA explained - −3.29%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $108.10MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own ORMP DCF in Excel. Value Oramed Pharmaceuticals with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00down 100.0%
- Net income
- $174.87M
- Diluted EPS
- $4.12
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$19.62M | −$0.48 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$10.19M | −$0.26 |
| Q1 FY25 (Mar 31, 2025) | $2.00M | −$7.64M | −$0.19 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | $13.29M | $0.31 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | $48.40M | $1.13 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | $10.01M | $0.24 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | $38.31M | $0.91 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | $78.16M | $1.84 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Aug 31, 2021) | $2.70M | −$22.24M | −$0.78 |
| FY22 (Dec 31, 2022) | $2.70M | −$36.56M | −$0.94 |
| FY23 (Dec 31, 2023) | $1.34M | $5.53M | $0.14 |
| FY24 (Dec 31, 2024) | $0.00 | −$19.06M | −$0.48 |
| FY25 (Dec 31, 2025) | $2.00M | $64.05M | $1.50 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$5.19MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$5.21MLast 12 months
- Capital spending$16.00KLast 12 months
Shareholder returns
- $4.37MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$10.44MLast 12 months
- Total returned$14.81MLast 12 months
Balance sheet
- $363.73MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$733.00KAs of Jun 30, 2026
- Net cash$363.00MAs of Jun 30, 2026
- 4.98As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 73.0%Last 12 months
Over the last 12 months, Oramed Pharmaceuticals’s net income was 73.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return. ROE can run this high when equity is small, for example after years of large share buybacks.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 64.2%Last 12 months
Over the last 12 months, Oramed Pharmaceuticals’s net income was 64.2% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
Dividends
Cash dividends per share by ex-dividend year, adjusted for splits.
Dividends per share
Data table
| Year | Per share |
|---|---|
| 2016 | $0.000 |
| 2017 | $0.000 |
| 2018 | $0.000 |
| 2019 | $0.000 |
| 2020 | $0.000 |
| 2021 | $0.000 |
| 2022 | $0.000 |
| 2023 | $0.000 |
| 2024 | $0.000 |
| 2025 | $0.000 |
| 2026 (to date) | $0.25 |
Dividend details
- $0.25Per share, last 12 months
Cash dividends per share with ex-dividend dates in the last 12 months.
- 6.48%; 5-yr low 4.68%, 5-yr high 7.89%Last 12 months
Dividends paid over the last 12 months as a share of the Nov 6 close. The bar shows where that yield sits in its range over the past five years; the median was 6.22%.
- $0.25Ex-dividend
The most recent payment per share. Shares bought on or after the ex-dividend date don’t receive it.
- 6.1%Last 12 months
The share of earnings paid out as dividends over the last 12 months. Lower ratios leave more room to reinvest or raise the dividend.
Payout = Dividends per share ÷ Diluted EPS (both last 12 months)Payout ratio calculator
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) is a diversified operating company that deploys capital across the biomedical and broader investment landscape, leveraging deep industry relationships, regulatory expertise, and operational experience to build and actively support a diversified portfolio of holdings.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New York, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ORMP news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ORMP stock FAQ
What is ORMP stock’s price today?
Oramed Pharmaceuticals (ORMP) traded at $3.86 at the close on , down $0.03 (0.77%) from the previous close of $3.89. Over the past 52 weeks it has traded between $2.19 and $5.47.
If you invested $1,000 in ORMP 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ORMP on would be worth about $687 at the close on , a total return of −31.3%. The same $1,000 would be worth $154 if invested five years ago, $1,874 if invested one year ago, and $414 if invested 20 years ago. Past performance doesn’t predict future returns.
What is Oramed Pharmaceuticals’s market cap?
Oramed Pharmaceuticals’s market capitalization is about $158.0 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $3.86 (how market cap works). Oramed Pharmaceuticals reported 40.93M shares outstanding at the end of its latest quarter ().
What is ORMP’s P/E ratio?
ORMP trades at 0.9 times its diluted earnings over the four quarters to ($4.12 per share), at the close. Over the past five years its P/E has ranged from 0.9 to 26.1, with a median of 2.7. (How the P/E ratio works.)
What are ORMP’s earnings per share?
ORMP’s diluted earnings per share were $4.12 over the four quarters to , compared with −$0.62 in the twelve months before. The latest quarter (Q2 FY26) brought $1.84 per share, against $0.31 a year earlier (how EPS works).
Does ORMP pay a dividend?
Oramed Pharmaceuticals paid dividends in the last twelve months. The most recent was $0.25 per share, with an ex-dividend date of . Over the last twelve months it paid $0.25 per share, a 6.48% yield at the close (how dividend yield works).
What is ORMP’s 52-week high and low?
Over the past 52 weeks ORMP has traded as low as $2.19 and as high as $5.47. At $3.86 at the close on , it is 29.4% below that high and 76.4% above the low.
What is ORMP’s all-time high?
ORMP’s highest closing price was $29.75 on , adjusted for stock splits. At $3.86 at the close on , it is 87.0% below that record.
Has ORMP stock ever split?
Yes, once: 1-for-12 on .
How has ORMP stock performed?
Including dividends and measured to the close on , ORMP has returned +44.6% so far this year and +87.4% over the past year, and −84.6% over five years (−31.2% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Oramed Pharmaceuticals in?
Oramed Pharmaceuticals is in the Healthcare sector and the Biotechnology industry, and is headquartered in New York, USA.
What exchange does ORMP trade on?
Oramed Pharmaceuticals trades on the Nasdaq under the ticker symbol ORMP. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.